Tech Transfer eNews Blog

Novoheart licenses Harvard technology to develop enhanced “human heart-in-a-jar”


By Jesse Schwartz
Published: January 8th, 2020

Novoheart, a global stem cell biotech company and pioneer of the “human heart-in-a-jar” model for drug development, has licensed a technology from Harvard University to complement its MyHeart Platform.

Developed in the lab of Harvard researcher Kevin Kit Parker, the licensed bioreactor technology involves a tissue-engineered scale model of the heart ventricle. Combined with Novoheart’s MyHeart Platform, the technology from Parker’s lab could lead to a next-generation heart-in-a-jar that offers a superior human heart model for disease modeling and drug development.

“By integrating Harvard’s valved bioreactor technology with our own proprietary human heart-in-a-jar, Novoheart will advance its disease modeling capabilities to an unprecedented level of biofidelity for in vitro human cardiac assays,” says Novoheart co-founder and chief scientific officer Kevin Costa. “The models can be directly applied to the discovery of new therapeutics targeting such diseases.”

Parker comments, “It is gratifying to see our innovations adopted into a platform with immediate relevance to the discovery and development of new therapeutics.”

The MyHeart Platform is currently in use by its various pharma and biotech clients. Novoheart anticipated that the Harvard technology, which it licensed through the university’s Office of Technology Development, will broaden Novoheart’s opportunities for drug development and commercialization.

Source: GlobeNewswire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment